Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in systemic lupus erythematosus, and Humacyte’s bioengineered vessel outperforms arteriovenous fistula in female dialysis patients.
This week’s readouts were defined by two major medical congresses: the American Diabetes Association’s 2026 Scientific Sessions in New Orleans and the European Alliance of Associations for Rheumatology Congress in London, each delivering data that will shape near-term prescribing and regulatory conversations in their respective fields. The obesity and metabolic disease result is particularly consequential: by demonstrating that meaningful weight reduction can be accompanied by disproportionate and organ-targeted reductions in visceral and liver fat, the SYNCHRONIZE programme makes a substantive case that dual receptor agonism may offer a metabolically richer profile than weight loss alone. Simultaneously, autoimmunity saw important advances in two high-burden conditions, a chronic inflammatory disease affecting older adults that has long lacked a steroid-sparing targeted option, and systemic lupus erythematosus, a complex multi-organ disease with a very limited approved treatment landscape. A Phase 3 bioengineering result in vascular surgery rounds out a week that reflects the full therapeutic breadth of the global pipeline. Here, Life Science Daily News brings you the most significant clinical trial results 12 June 2026.
Boehringer Ingelheim and Zealand Pharma’s Survodutide Delivers Dual Phase 3 Success in Obesity and Metabolic Liver Disease at ADA 2026
Boehringer Ingelheim announced on 7 June 2026 positive results from two global Phase 3 trials of survodutide (BI 456906), a once-weekly subcutaneous glucagon receptor and GLP-1 receptor dual agonist developed in collaboration with Zealand Pharma. Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans and simultaneously published in The New England Journal of Medicine and Nature Medicine respectively. SYNCHRONIZE-1 is a 76-week, randomised, double-blind, placebo-controlled Phase 3 trial evaluating survodutide in adults with obesity or overweight without type 2 diabetes. At the highest studied dose of 6 mg, survodutide achieved mean body weight reductions of 13.0 per cent versus 5.4 per cent for placebo on the treatment-regimen estimand, with 16.6 per cent reduction on the efficacy estimand. 28.7 per cent of patients on the 6 mg dose lost at least 20 per cent of their body weight. A prespecified MRI substudy provided further differentiation: at the 6 mg dose, liver fat fell by 63.1 per cent and visceral fat by 34 per cent relative to baseline, while lean mass accounted for no more than 10.8 per cent of the change in total tissue mass at the highest dose, indicating that weight loss was driven predominantly by fat rather than muscle.
SYNCHRONIZE-MASLD was a 48-week Phase 3 study in 218 adults with obesity or overweight and MASLD with evidence of inflammation or fibrosis. The trial met both co-primary endpoints: up to 84.2 per cent of survodutide-treated participants achieved at least a 30 per cent relative liver fat reduction versus 24.3 per cent for placebo (p<0.0001), and body weight fell by up to 12.2 per cent versus 1.0 per cent for placebo (p<0.0001). Liver fat normalisation was observed in 61 per cent of treated patients after 48 weeks. Both trials reported a tolerability profile consistent with the GLP-1 class; nausea, vomiting, and diarrhoea were the most commonly reported adverse events. Survodutide is not yet approved in any market.
Novartis’ Cosentyx Achieves Sustained Remission in Polymyalgia Rheumatica in the Phase 3 REPLENISH Trial
This story was presented at the EULAR 2026 Congress on 3 June and published in The New England Journal of Medicine on the same date, falling on the boundary of this edition’s coverage window. Given the significance of the data and its continued presence in clinical discussion across the week of 6–12 June, Life Science Daily News is covering it here.
Novartis announced on 3 June 2026 that Cosentyx (secukinumab) met the primary endpoint and all secondary endpoints in the Phase 3 REPLENISH trial, the largest global Phase 3 study conducted in polymyalgia rheumatica (PMR). Data were simultaneously published in The New England Journal of Medicine and presented in an oral session at the European Alliance of Associations for Rheumatology (EULAR) Congress in London. REPLENISH (NCT05767034) is a global, multicentre, randomised, double-blind, placebo-controlled, parallel-group study conducted across 27 countries in patients with PMR. Participants were randomised to one of three treatment arms, secukinumab 300 mg, secukinumab 150 mg, or placebo, all in combination with a 24-week steroid tapering regimen. The primary endpoint was sustained remission at week 52, defined as the absence of relapse and absence of the need for additional treatment. Secukinumab achieved statistically significant and clinically meaningful sustained remission rates versus placebo: 41.2% of patients on the 300 mg dose and 40.6% on the 150 mg dose achieved sustained remission at week 52, compared with 20.4% on placebo (both p<0.001), representing approximately twice the remission rate of placebo across both doses. Significant steroid sparing was also demonstrated, a particularly meaningful finding given the well-documented burden of chronic corticosteroid exposure in the predominantly elderly PMR population, where side effects including osteoporosis, hyperglycaemia, and cardiovascular risk are compounding concerns.
PMR is a common inflammatory rheumatic disease in adults over 50, characterised by bilateral pain and stiffness in the neck, shoulders, or hips alongside morning stiffness and fatigue. Management has historically relied on long-term corticosteroids, which carry a well-documented adverse effect burden including osteoporosis, hyperglycaemia, and cardiovascular risk in an already vulnerable population. Secukinumab is an interleukin-17A inhibitor already approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. If approved for PMR, it would represent the first IL-17A inhibitor approved for the condition, adding a mechanistically distinct option to the treatment landscape alongside sarilumab, an IL-6 receptor inhibitor approved by the FDA for PMR in 2023.
UCB and Biogen’s Dapirolizumab Pegol Meets Phase 3 Primary Endpoint in Systemic Lupus Erythematosus in PHOENYCS GO
Full results from the PHOENYCS GO study were published in The Lancet on 1 June 2026, and additional data from the trial were presented at the EULAR 2026 Congress on 4 June, placing this story on the boundary of this edition’s coverage window. Given the scale of the unmet need and the ongoing clinical discussion of these data during the week of 6–12 June, Life Science Daily News is covering it here.
UCB and Biogen announced on 1 June 2026 the publication in The Lancet of full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational novel Fc-free CD40L inhibitor, in patients with moderate-to-severe active systemic lupus erythematosus (SLE). PHOENYCS GO (NCT04294667) is a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 study enrolling 321 patients. The trial met its primary endpoint: a significantly greater proportion of patients receiving DZP plus standard of care (SOC) achieved British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at week 48 compared to placebo plus SOC, at 50 per cent (103 of 208 patients) versus 35 per cent (37 of 107 patients; p=0.011). BICLA is a composite endpoint measuring clinically relevant improvement of disease activity across all affected organ systems with no worsening in other lupus domains. DZP plus SOC was also associated with sustained disease control at lower glucocorticoid doses through week 48, supporting reduced long-term steroid exposure, and demonstrated improvements in immunological markers and reduced flare rates.
SLE is a complex, heterogeneous autoimmune disease affecting multiple organ systems, characterised by periods of flare and remission, with a limited approved treatment landscape. Belimumab and anifrolumab are the most recently approved targeted agents. Dapirolizumab pegol is a humanised Fc-free PEG-conjugated antigen-binding fragment targeting CD40L, a co-stimulatory molecule involved in B-cell activation and autoantibody production. The Fc-free design is intended to eliminate the thrombotic risk associated with earlier CD40L-targeting agents. An important caveat: the first key secondary endpoint of BICLA response at week 24 was not met, meaning subsequent outcomes were not controlled for multiplicity. The confirmatory Phase 3 PHOENYCS FLY trial is currently recruiting.
Humacyte’s Acellular Tissue Engineered Vessel Meets Phase 3 Primary Endpoint in Female Dialysis Access in V012 Study
Humacyte announced on 10 June 2026 positive top-line interim results from the Phase 3 V012 clinical trial evaluating its acellular tissue engineered vessel (ATEV) as a dialysis access solution in female patients with end-stage renal disease (ESKD) requiring haemodialysis. The ATEV met the study’s primary endpoint with statistical significance, demonstrating superior catheter-free days compared with autologous arteriovenous (AV) fistula, the current standard of care (p=0.00070). In the prespecified interim analysis conducted in the first 80 patients enrolled, patients implanted with the ATEV achieved an average of 220 catheter-free days compared to 129 catheter-free days for patients who received an AV fistula, a difference of 91 days. Multiple secondary endpoints also showed consistent advantages in favour of the ATEV. On the primary safety measure of access-related infections, ATEV patients incurred infections at a rate of 6 per 100 patient-years compared to 23 per 100 patient-years for patients in the AV fistula arm, with no study access-associated infections reported in the ATEV group. No spontaneous ruptures were reported in either treatment arm. The overall benefit-risk profile was considered favourable with no new or unexpected safety signals. Results were presented on 11 June at the Society for Vascular Surgery’s Vascular Annual Meeting in Boston.
V012 is a Phase 3, prospective, multicentre, open-label, randomised study conducted in the United States in up to 150 patients, with 120 enrolled at the time of interim analysis. The planned supplemental BLA targets adult ESKD patients at increased risk of AV fistula maturation failure. Female haemodialysis patients are disproportionately affected by fistula failure, attributed to differences in vessel diameter and anatomy, leaving many dependent on central venous catheters, which carry substantial infection, thrombosis, and mortality risk with prolonged use. The ATEV is a human-derived, decellularised bioengineered vessel that requires no donor matching and supports host cell repopulation over time. It holds existing FDA approval for extremity vascular injury and RMAT and Fast Track designations for the AV access indication. Humacyte plans to file the sBLA in the second half of 2026.
Looking Ahead
The clinical trial results 12 June 2026 reflect a week during which two of the world’s largest medical congresses delivered data with direct implications for high-burden, chronically underserved conditions. Survodutide’s dual Phase 3 success in obesity and MASLD makes a compelling case that organ-selective fat reduction may become a new benchmark for evaluating metabolic therapies beyond body weight alone. The REPLENISH result for secukinumab in PMR addresses a genuine unmet need where clinicians have long faced a difficult choice between corticosteroid dependence and relapse, and regulatory submissions in multiple jurisdictions make near-term approvals realistic. The PHOENYCS GO result for dapirolizumab pegol in SLE clears the primary endpoint in a notoriously difficult indication, though the multiplicity caveat warrants careful reading as PHOENYCS FLY continues. And Humacyte’s V012 result addresses a specific equity gap in dialysis care with a bioengineered product that outperforms current standards in a population where fistula failure is substantially more common. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 12 June 2026 that matter most across the global life sciences pipeline.
This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently.
